Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Rhea-AI Summary

Biofrontera (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological products commercialization, has scheduled its Second Quarter 2025 Financial Results announcement for August 13, 2025 after market close.

The company will host a conference call and webcast to discuss the results on Thursday, August 14, 2025, at 10:00 AM ET. Investors can access the call via U.S. toll-free number (1-877-877-1275) or international number (1-412-858-5202).

News Market Reaction – BFRI

-3.37%

1 alert

-3.37% Session close to close

$9.49M Market Cap

0.4x Rel. Volume

In the Aug 4 session, BFRI declined 3.37%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.

Conference Call and Webcast Information

Event:	Biofrontera Inc. Second Quarter 2025 Financial Results and Business Update Conference Call
Date:	Thursday, August 14, 2025
Time:	10:00am ET
Conference Call:	1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast:	Webcast | Second Quarter 2025 Financial Results and Business Update Conference Call

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ^® with the RhodoLED ^® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com

FAQ

When will Biofrontera (BFRI) release Q2 2025 earnings?

Biofrontera will release its Q2 2025 financial results on Wednesday, August 13, 2025 after market close.

How can investors join Biofrontera's Q2 2025 earnings call?

Investors can join the call on August 14, 2025 at 10:00 AM ET by dialing 1-877-877-1275 (U.S.) or 1-412-858-5202 (international).

What is Biofrontera's (BFRI) main business focus?

Biofrontera is a biopharmaceutical company specializing in the commercialization of dermatological products.

What period will Biofrontera's Q2 2025 earnings report cover?

The earnings report will cover the three and six months ended June 30, 2025.